for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pharma Mar SA

PHMR.MC

現在値

9.90EUR

変化

0.07(+0.71%)

出来高

1,870,198

本日のレンジ

9.71

 - 

9.96

52週レンジ

1.47

 - 

9.96

∙ 約20分前の相場を表示しています。

価格

前日終値
9.83
始値
9.75
出来高
1,870,198
3か月平均出来高
55.64
高値
9.96
安値
9.71
52週高値
9.96
52週安値
1.47
発行済株式数
221.96
時価総額
2,117.40
予想PER
13.19
配当利回り
0.42

次のエベント

Pharma Mar SA Annual Shareholders Meeting

適時開示

その他

Pharma Mar's Lurbinectedin Receives Acceptance For Clinical Trial Application In China

Pharma Mar Receives Payment Of 100 Mln Dollars From Jazz Pharmaceuticals For Lurbinectedin US Approval

Pharma Mar: US FDA Approves Lurbinectedin To Treat Metastatic Small Cell Lung Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pharma Mar SAとは

Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.

業種

Biotechnology & Drugs

連絡先

Avda. De los Reyes, 1, Pol. Ind. La Mina

COLMENAR VIEJO, MAD

28770

Spain

+34.918.466000

https://www.pharmamar.com/es/

エグゼクティブリーダーシップ

Jose Maria Fernandez Sousa-Faro

President, Chief Executive Officer, Executive Chairman of the Board

Pedro Fernandez Puentes

Executive Vice Chairman

Maria Luisa de Francia Caballero

Chief Financial Officer

Nadia Badri

Vice President - Medical Affairs

Carmen Cuevas Marchante

Director of Research & Development

統計

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.2K

2018

0.2K

2019

0.1K

2020(E)

0.3K
EPS (EUR)

2017

-0.120

2018

-0.300

2019

-0.050

2020(E)

0.721
株価売上高倍率(過去12カ月)
29.46
株価売上高倍率(過去12カ月)
12.77
株価純資産倍率(四半期)
25.96
株価キャッシュフロー倍率
26.70
総負債/総資本(四半期)
78.27
長期負債/資本(四半期)
55.44
投資利益率(過去12カ月)
51.83
自己資本利益率(過去12カ月)
32.52

最新ニュース

最新ニュース

新型コロナ、約10種の既存薬化合物が有効な可能性=米仏研究者

体内での新型コロナウイルスの増殖を防ぐ上で、がん治療薬や抗精神病薬、抗ヒスタミン薬などで使用されている少なくとも10種類の薬剤化合物が有効である可能性が、米国とフランスの科学者らによる研究で明らかになった。

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up